Home/Pipeline/Undisclosed Brain Infusion Program

Undisclosed Brain Infusion Program

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

InBrain Pharma

About InBrain Pharma

InBrain Pharma is a Paris-based, private biotech developing targeted brain infusion therapies for neurological disorders, with a primary focus on Parkinson's disease. The company leverages a strong scientific foundation from its co-founders and advisors, who are leading neurologists and researchers in movement disorders. While currently pre-revenue and in the pre-clinical/early clinical stage, InBrain is positioning itself in the advanced therapy segment of the neurodegenerative disease market. Its strategy involves overcoming the blood-brain barrier to deliver therapeutics directly to the brain, aiming for superior efficacy and personalized treatment paradigms.

View full company profile

Therapeutic Areas

Parkinson's Disease Neurological Disorders

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active